Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
More than 25 years after the US Bayh-Dole Act was passed to encourage technology transfer from universities, is it time to reexamine and revamp this key legislation?
A survey of the ethical practices of bioscience companies suggests that although most firms feature ethics in their mission statement or code of conduct, fewer than half of the companies surveyed have made any formal efforts to assess how well these approaches are working.
Biotech companies will be facing particular ethical challenges as their products enter the marketplace. How is the industry preparing? Ken Wilan investigates.
The faculty director of the newly established bioethics center at Harvard Law School believes that law is the framework for looking at all the issues relevant to the delivery of healthcare, from malpractice to insurance to patents.